WPD Pharmaceuticals Inc. (WPDPF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 171.5 Thousand USD | -89.91% |
| 2022 | 1.7 Million USD | -64.4% |
| 2021 | 4.77 Million USD | -24.56% |
| 2020 | 6.33 Million USD | -28.15% |
| 2019 | 8.81 Million USD | 1557.93% |
| 2018 | 531.51 Thousand USD | 54.21% |
| 2017 | 344.67 Thousand USD | 126.0% |
| 2016 | 152.51 Thousand USD | 1017.21% |
| 2015 | 13.65 Thousand USD | -67.71% |
| 2014 | 42.27 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 62.94 Thousand USD | -35.35% |
| 2024 Q1 | 101.45 Thousand USD | 56.46% |
| 2023 FY | 202.89 Thousand USD | -88.07% |
| 2023 Q3 | 46.07 Thousand USD | -24.13% |
| 2023 Q1 | 28.07 Thousand USD | -67.23% |
| 2023 Q2 | 60.73 Thousand USD | 116.34% |
| 2023 Q4 | 66.27 Thousand USD | 43.82% |
| 2022 Q4 | 85.67 Thousand CAD | -90.24% |
| 2022 FY | 1.7 Million USD | -64.4% |
| 2022 Q1 | 491.09 Thousand USD | -58.99% |
| 2022 Q3 | 878.03 Thousand CAD | 52.53% |
| 2022 Q2 | 575.64 Thousand USD | 17.22% |
| 2021 Q4 | 1.19 Million USD | 36.13% |
| 2021 Q1 | 1.69 Million USD | 35.16% |
| 2021 FY | 4.77 Million USD | -24.56% |
| 2021 Q3 | 879.69 Thousand USD | -14.53% |
| 2021 Q2 | 1.02 Million USD | -39.4% |
| 2020 Q3 | 1.16 Million USD | -32.56% |
| 2020 FY | 6.33 Million USD | -28.15% |
| 2020 Q4 | 1.25 Million USD | 7.47% |
| 2020 Q2 | 1.73 Million USD | 0.0% |
| 2019 FY | 8.81 Million USD | 1557.93% |
| 2018 FY | 531.51 Thousand USD | 54.21% |
| 2017 FY | 344.67 Thousand USD | 126.0% |
| 2016 FY | 152.51 Thousand USD | 1017.21% |
| 2015 FY | 13.65 Thousand USD | -67.71% |
| 2014 FY | 42.27 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 87.157% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 96.598% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.42% |
| Nascent Biotech, Inc. | 2.22 Million USD | 92.309% |
| Rebus Holdings, Inc. | 664 Thousand USD | 74.17% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.54% |
| Qrons Inc. | 643.67 Thousand USD | 73.355% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 55.974% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.701% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 58.72% |
| Skye Bioscience, Inc. | 13.54 Million USD | 98.734% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.802% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 96.513% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 34.47% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.8% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 94.119% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 88.581% |
| Mesoblast Limited | 5.9 Million USD | 97.094% |
| Marizyme, Inc. | 19.23 Million USD | 99.109% |
| Genus plc | 147.7 Million USD | 99.884% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 98.046% |
| Pharming Group N.V. | 225.49 Million USD | 99.924% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 91.628% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 87.216% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 97.943% |
| ContraFect Corporation | 56.88 Million USD | 99.699% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 96.11% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 88.402% |
| IMV Inc. | 37.7 Million USD | 99.545% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 93.854% |
| MultiCell Technologies, Inc. | 567.42 USD | -30126.111% |
| ONE Bio Corp. | 6.44 Million USD | 97.338% |
| Accustem Sciences Inc. | 3.74 Million USD | 95.422% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.8% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | 67.759% |
| Q BioMed Inc. | 3.43 Million USD | 95.009% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 99.306% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 93.473% |
| Biomind Labs Inc. | 994.18 Thousand USD | 82.749% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.827% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 90.253% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 97.447% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 90.801% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 786.036% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 98.929% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 90.654% |
| GB Sciences, Inc. | 1.42 Million USD | 87.926% |
| Alpha Cognition Inc. | 9.7 Million USD | 98.233% |
| HST Global, Inc. | 140.9 Thousand USD | -21.718% |
| CSL Limited | 3.44 Billion USD | 99.995% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 84.754% |
| Halberd Corporation | 74.84 Thousand USD | -129.161% |
| Enzolytics Inc. | 2.17 Million USD | 92.131% |
| Agentix Corp. | 1.37 Million USD | 87.497% |
| Resverlogix Corp. | 12.71 Million USD | 98.651% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 95.302% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.989% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 83.572% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 92.868% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 89.141% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 94.963% |
| AVAX Technologies, Inc. | 7.31 Million USD | 97.654% |
| Zenith Capital Corp. | 8.94 Million USD | 98.082% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.979% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -884.496% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 93.015% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 91.071% |
| Kadimastem Ltd | 2.41 Million USD | 92.884% |
| Helix BioMedix, Inc. | 1.97 Million USD | 91.303% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 98.422% |
| BioStem Technologies, Inc. | 22.97 Million USD | 99.253% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 5.497% |
| LadRx Corporation | 3.81 Million USD | 95.501% |
| Cell Source, Inc. | 4.32 Million USD | 96.035% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 81.429% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 81.429% |
| NovAccess Global Inc. | 2.46 Million USD | 93.047% |
| Affymax, Inc. | 39.38 Million USD | 99.565% |
| Itoco Inc. | 919.14 Thousand USD | 81.34% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 95.953% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 84.673% |
| Mobile Lads Corp. | 554.54 Thousand USD | 69.072% |
| CytoDyn Inc. | 18.05 Million USD | 99.05% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -581.43% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 22.069% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 87.92% |
| SYBLEU INC | 160.87 Thousand USD | -6.609% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 90.557% |
| International Stem Cell Corporation | 5.27 Million USD | 96.746% |
| Bioxytran, Inc. | 3.82 Million USD | 95.51% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -225.803% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -743.086% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.527% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 89.4% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 76.692% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 94.487% |
| Neutra Corp. | 243.82 Thousand USD | 29.658% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 99.018% |
| PureTech Health plc | 144.59 Million USD | 99.881% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 99.163% |
| IXICO plc | 4.7 Million USD | 96.356% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 98.05% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.854% |
| CSL Limited | 3.89 Billion USD | 99.996% |
| Cellectis S.A. | 97.32 Million USD | 99.824% |